December 23, 2025

Vyriad: Final $25 Million Series B Tranche Closed To Advance In Vivo CAR T Candidate Into Clinic

Vyriad, a Rochester, Minnesota-based clinical-stage biotechnology company developing targeted genetic therapies, said it has closed a $25 million final tranche of its Series B financing, bringing the round’s total to $85 million.